Loading stock data…
Aytu BioPharma (AYTU)
$2.16
Market ClosedLast close Jul 24
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Aytu BioPharma, Inc. in the Healthcare sector is trading at $2.16 with a market capitalization of $22M. Wall Street consensus targets $9.50 (3 analysts), implying a +339.8% move over the next 12 months. The stock is currently 30% below its 52-week high of $3.07, remaining 9.2% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +339.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $12.41M↓ | $15.16M↑ | $13.89M↓ | $15.13M↓ | $18.45M |
| Gross Profit | $7.60M↓ | $9.62M↑ | $9.19M↓ | $10.25M↓ | $12.81M |
| Operating Income | -$4.06M↓ | -$1.97M↓ | -$1.50M↓ | $640,000↓ | $2.42M |
| Net Income | -$5.62M↑ | -$10.58M↓ | $1.97M↑ | -$19.82M↓ | $3.99M |
Peer Comparison
JNJUNHPFE
Fundamentals
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), inc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$22.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-96.90%
Volume
Today's trading volume
10,374
Recent News
New Strong Sell Stocks for July 20th
ACR, AEM and AYTU have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2026.
New Strong Sell Stocks for July 16th
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aytu BioPharma, Inc.'s Q3 2026 earnings call
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Strong Exua Adoption Amid Revenue ...
Aytu BioPharma Inc (AYTU) reports robust initial traction for Exua despite a decline in net revenue and profit margins.
Aytu (AYTU) Q3 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? As the operator indicated, during today's call, we will be discussing Aytu BioPharma's fiscal 26 third quarter operational and financial results. Joining us on today's call is Aytu's chief executive officer, Joshua R. Disbrow and Ryan J. Selhorn, the company's chief financial officer.